<DOC>
	<DOCNO>NCT01628692</DOCNO>
	<brief_summary>The purpose study assess safety efficacy daclatasvir simeprevir without ribavirin genotype 1 chronic hepatitis C virus infection patient treatment-naive null responder previous pegylated interferon/ribavirin therapy .</brief_summary>
	<brief_title>Study Daclatasvir ( BMS-790052 ) Simeprevir ( TMC435 ) Patients With Genotype 1 Chronic Hepatitis C Virus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Key Hepatitis C virus ( HCV ) genotype 1a 1b Males female , ≥18 year age HCV RNA ≥10,000 IU/mL Participants compensate cirrhosis permit Advanced fibrosis ( F3/F4 ) cap approximately 35 % total treated population minimum 20 % F4 patient If cirrhosis , liver biopsy within 3 year prior enrollment If cirrhosis present , prior liver biopsy Key Liver transplant ( cornea hair ) Evidence medical condition contribute chronic liver disease HCV infection Current known history cancer , ( except situ carcinoma cervix adequately treat basal squamous cell carcinoma skin ) within 5 year prior enrollment Evidence decompensated liver disease include , limited , radiologic criterion , history presence ascites , bleed varix , hepatic encephalopathy Patients infect HIV hepatitis B virus Gastrointestinal disease impact absorption study drug Uncontrolled diabetes hypertension Prior exposure HCV directacting agent Any criterion would exclude patient receive ribavirin Absolute neutrophil count &lt; 1.5*1,000,000,000 cells/L ( &lt; 1.2*1,000,000,000 cells/L Black/African Americans ) Platelets &lt; 90*1,000,000,000 cells/L Hemoglobin &lt; 12 g/dL female , &lt; 13 g/dL male Alanine aminotransferase ≥5*upper limit normal In patient without cirrhosis , total bilirubin ≥2 mg/dL unless patient documented history Gilbert 's disease In patient cirrhosis , total bilirubin ≥1.5 mg/dL International normalized ratio ≥1.7 QTcF QTcB &gt; 500 mSec Creatinine clearance ≤50 mL/min Alpha fetoprotein ( AFP ) &gt; 100 ng/mL OR AFP ≥50 ng/mL ≤100 ng/mL require liver ultrasound Albumin &lt; 3.5 g/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>